Study of Interferon Gamma-1b by Injection for the Treatment of Patients With Cystic Fibrosis

• Status: Completed
• Trial end date: 2003-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this research study is to evaluate the safety, tolerability, and efficacy of Interferon gamma-1b (IFN-gamma 1b) when administered by subcutaneous injection over a period of 4 weeks to patients with mild-to-moderate cystic fibrosis. Additionally, preliminary assessments on the effects of IFN-gamma 1b on lung function and other indicators of health will be made.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: InterMune
• Treatments: Interferon-gamma; Interferons

Criteria

• At least 6 years of age

• Diagnosis of cystic fibrosis (against certain criteria)

• Able to perform pulmonary (lung) function tests and participate in induced sputum procedures

• Pulmonary function values must meet certain minimal requirements

• Must have acceptable laboratory test results

• Cannot be on certain medications during and immediately prior to study

• Cannot have a history of unstable or deteriorating cardiac or neurologic disease